Osteoporosis Treatment Guidelines

Introduction to Osteoporosis Management

The American Academy of Family Physicians recommends that patients with a T-score of -3.5 should be initiated on bisphosphonates as first-line therapy, with consideration for anabolic agents if there is a history of vertebral or hip fracture, or if the patient is at very high fracture risk 1, 2, 3

Oral bisphosphonates are the standard first-line treatment for patients with T-scores ≤ -2.5, which includes patients with a T-score of -3.5, according to the American Academy of Family Physicians 1, 2, 3
The American Academy of Family Physicians suggests specific bisphosphonate options, including alendronate 70 mg once weekly, risedronate 35 mg once weekly, ibandronate 150 mg once monthly, and zoledronic acid 5 mg IV annually 1, 2
Anabolic therapy should be considered as initial treatment if the patient has a recent vertebral fracture, history of hip fracture with T-score ≤ -2.5, multiple prevalent fractures, or very high 10-year fracture risk, as recommended by the American Academy of Family Physicians and the American College of Radiology 1, 2, 3, 4, 5
The American Academy of Family Physicians recommends anabolic options, including teriparatide, abaloparatide, or romosozumab, for severe osteoporosis with fractures or very high-risk patients 1, 2, 3

The American Academy of Family Physicians and the Journal of Clinical Oncology recommend that all patients receive calcium 1,000-1,200 mg daily, vitamin D 800-1,000 IU daily, weight-bearing and resistance exercises, and smoking cessation and alcohol limitation 1, 2, 6

The American Academy of Family Physicians recommends that patients must be able to stand or sit upright for at least 30 minutes after taking oral bisphosphonates, take medication on an empty stomach with plain water, and have no esophageal abnormalities or swallowing difficulties 1, 2
The Journal of Clinical Oncology suggests BMD reassessment every 1-2 years to evaluate treatment response, and evaluation for secondary causes of osteoporosis, including serum calcium, phosphate, 25-hydroxyvitamin D, parathyroid hormone, thyroid function, and renal function 6, 7
The American Academy of Family Physicians recommends that treatment duration for bisphosphonates is typically 3-5 years, then reassess need for continuation, and anabolic agents should be used for a maximum of 18-24 months, followed by antiresorptive therapy to maintain gains 3